Dr. Reddy's Laboratories has disclosed receiving a regulatory setback from the United States Food and Drug Administration regarding its biosimilar development program. The pharmaceutical company announced that its wholly owned subsidiary Dr. Reddy's Laboratories SA, Switzerland has received a Complete Response Letter for its AVT03 biosimilar application.

Regulatory Development Details

The Complete Response Letter pertains to the Biologics License Application for AVT03, which is a proposed biosimilar candidate to denosumab products Prolia and Xgeva. The CRL specifically refers to observations from a pre-license inspection of Alvotech's Reykjavik manufacturing facility. The biosimilar has been developed in partnership with Alvotech hf, an Iceland-based biopharmaceutical company specializing in biosimilar development.

Manufacturing Facility Inspection

The CRL specifically references observations arising from a pre-license inspection conducted at Alvotech's manufacturing facility located in Reykjavik. Pre-license inspections are routine regulatory procedures where the FDA evaluates manufacturing facilities to ensure compliance with current Good Manufacturing Practices before approving new drug applications.

About AVT03 Biosimilar

AVT03 represents Dr. Reddy's entry into the denosumab biosimilar market. Denosumab is a monoclonal antibody used for treating osteoporosis and preventing skeletal-related events in patients with bone metastases from solid tumors. The reference products Prolia and Xgeva are established treatments in the bone health therapeutic area.

Partnership Structure

The biosimilar development involves a collaboration between Dr. Reddy's Swiss subsidiary and Alvotech hf. This partnership structure allows Dr. Reddy's to leverage Alvotech's biosimilar development expertise while utilizing its own regulatory and commercial capabilities for market access.

Regulatory Disclosure

The announcement was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders regarding material regulatory developments.

Dr Reddys Laboratories has received regulatory attention from the US Food and Drug Administration (USFDA) following an inspection at one of its key manufacturing facilities. The pharmaceutical company announced that the USFDA has completed its Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) review at the company's Srikakulam plant.

USFDA Inspection Outcome

Following the comprehensive review, the regulatory authority has issued a Form 483 to the company. This regulatory document identifies five specific concerns that were observed during the inspection process at the Srikakulam facility.

Understanding Form 483

Form 483 represents the USFDA's formal communication to pharmaceutical companies regarding observations made during facility inspections. When issued, it indicates that inspectors have identified conditions or practices that may constitute violations of food and drug laws and regulations.

Regulatory Implications

The issuance of Form 483 requires the company to provide a written response addressing each concern raised by the USFDA. Companies typically have 15 working days to respond with corrective actions and timelines for implementation. The pharmaceutical manufacturer will need to demonstrate how it plans to resolve the identified issues to maintain compliance with US regulatory standards.

This development at the Srikakulam facility represents a regulatory checkpoint that Dr Reddys Laboratories must navigate as part of its ongoing operations in the US pharmaceutical market. The company will need to address the five regulatory concerns cited by the USFDA to ensure continued compliance and smooth operations at the facility.